MEDPACE HOLDINGS INC (MEDP) Stock Fundamental Analysis
USA - NASDAQ:MEDP - US58506Q1094 - Common Stock
532.49 USD
-3.68 (-0.69%)
532.49 USD
0 (0%)
MEDP gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 56 industry peers in the Life Sciences Tools & Services industry. Both the health and profitability get an excellent rating, making MEDP a very profitable company, without any liquidiy or solvency issues. MEDP is growing strongly while it is still valued neutral. This is a good combination! With these ratings, MEDP could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
MEDP had positive earnings in the past year.
MEDP had a positive operating cash flow in the past year.
MEDP had positive earnings in each of the past 5 years.
In the past 5 years MEDP always reported a positive cash flow from operatings.
1.2 Ratios
MEDP's Return On Assets of 26.61% is amongst the best of the industry. MEDP outperforms 100.00% of its industry peers.
With an excellent Return On Equity value of 242.70%, MEDP belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
MEDP's Return On Invested Capital of 115.03% is amongst the best of the industry. MEDP outperforms 100.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for MEDP is significantly above the industry average of 14.93%.
The last Return On Invested Capital (115.03%) for MEDP is above the 3 year average (38.75%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.61% | ||
| ROE | 242.7% | ||
| ROIC | 115.03% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
1.3 Margins
MEDP has a better Profit Margin (18.74%) than 92.86% of its industry peers.
MEDP's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 21.40%, MEDP belongs to the top of the industry, outperforming 89.29% of the companies in the same industry.
In the last couple of years the Operating Margin of MEDP has grown nicely.
The Gross Margin of MEDP (31.62%) is worse than 67.86% of its industry peers.
In the last couple of years the Gross Margin of MEDP has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.4% | ||
| PM (TTM) | 18.74% | ||
| GM | 31.62% |
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so MEDP is creating value.
The number of shares outstanding for MEDP has been reduced compared to 1 year ago.
The number of shares outstanding for MEDP has been reduced compared to 5 years ago.
MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
MEDP has an Altman-Z score of 7.68. This indicates that MEDP is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 7.68, MEDP belongs to the top of the industry, outperforming 89.29% of the companies in the same industry.
There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 7.68 |
ROIC/WACC10.9
WACC10.55%
2.3 Liquidity
A Current Ratio of 0.43 indicates that MEDP may have some problems paying its short term obligations.
MEDP's Current ratio of 0.43 is on the low side compared to the rest of the industry. MEDP is outperformed by 98.21% of its industry peers.
MEDP has a Quick Ratio of 0.43. This is a bad value and indicates that MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
MEDP's Quick ratio of 0.43 is on the low side compared to the rest of the industry. MEDP is outperformed by 96.43% of its industry peers.
MEDP does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.43 | ||
| Quick Ratio | 0.43 |
3. Growth
3.1 Past
MEDP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.53%, which is quite impressive.
Measured over the past years, MEDP shows a very strong growth in Earnings Per Share. The EPS has been growing by 33.22% on average per year.
MEDP shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.94%.
MEDP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.62% yearly.
EPS 1Y (TTM)26.53%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%12.73%
Revenue 1Y (TTM)9.94%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%14.24%
3.2 Future
Based on estimates for the next years, MEDP will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.11% on average per year.
Based on estimates for the next years, MEDP will show a quite strong growth in Revenue. The Revenue will grow by 10.93% on average per year.
EPS Next Y13.52%
EPS Next 2Y11.72%
EPS Next 3Y11.39%
EPS Next 5Y10.11%
Revenue Next Year16.85%
Revenue Next 2Y12.67%
Revenue Next 3Y11.46%
Revenue Next 5Y10.93%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 39.59 indicates a quite expensive valuation of MEDP.
Based on the Price/Earnings ratio, MEDP is valued a bit cheaper than 60.71% of the companies in the same industry.
MEDP's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 27.86.
With a Price/Forward Earnings ratio of 33.78, MEDP can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, MEDP is valued a bit cheaper than the industry average as 64.29% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.32, MEDP is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.59 | ||
| Fwd PE | 33.78 |
4.2 Price Multiples
60.71% of the companies in the same industry are more expensive than MEDP, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, MEDP is valued cheaper than 80.36% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.8 | ||
| EV/EBITDA | 29.44 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
MEDP has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)2.93
PEG (5Y)1.19
EPS Next 2Y11.72%
EPS Next 3Y11.39%
5. Dividend
5.1 Amount
No dividends for MEDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
532.49
-3.68 (-0.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners94.93%
Inst Owner Change0%
Ins Owners0.54%
Ins Owner Change-1.26%
Market Cap14.96B
Analysts52.94
Price Target433.15 (-18.66%)
Short Float %9.86%
Short Ratio4.48
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.2%
Min EPS beat(2)2.57%
Max EPS beat(2)17.84%
EPS beat(4)4
Avg EPS beat(4)12.05%
Min EPS beat(4)2.57%
Max EPS beat(4)21.62%
EPS beat(8)8
Avg EPS beat(8)12.09%
EPS beat(12)11
Avg EPS beat(12)14.32%
EPS beat(16)15
Avg EPS beat(16)14.6%
Revenue beat(2)2
Avg Revenue beat(2)6.91%
Min Revenue beat(2)4.04%
Max Revenue beat(2)9.78%
Revenue beat(4)2
Avg Revenue beat(4)2.21%
Min Revenue beat(4)-3.35%
Max Revenue beat(4)9.78%
Revenue beat(8)3
Avg Revenue beat(8)0.5%
Revenue beat(12)7
Avg Revenue beat(12)1.63%
Revenue beat(16)8
Avg Revenue beat(16)1%
PT rev (1m)4.12%
PT rev (3m)41.21%
EPS NQ rev (1m)-0.09%
EPS NQ rev (3m)16.86%
EPS NY rev (1m)0.06%
EPS NY rev (3m)10.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)18%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)12.7%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.59 | ||
| Fwd PE | 33.78 | ||
| P/S | 6.7 | ||
| P/FCF | 25.8 | ||
| P/OCF | 24.36 | ||
| P/B | 86.79 | ||
| P/tB | N/A | ||
| EV/EBITDA | 29.44 |
EPS(TTM)13.45
EY2.53%
EPS(NY)15.76
Fwd EY2.96%
FCF(TTM)20.64
FCFY3.88%
OCF(TTM)21.86
OCFY4.11%
SpS79.45
BVpS6.14
TBVpS-18.65
PEG (NY)2.93
PEG (5Y)1.19
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.61% | ||
| ROE | 242.7% | ||
| ROCE | 135.95% | ||
| ROIC | 115.03% | ||
| ROICexc | 132.51% | ||
| ROICexgc | N/A | ||
| OM | 21.4% | ||
| PM (TTM) | 18.74% | ||
| GM | 31.62% | ||
| FCFM | 25.98% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
ROICexc(3y)71.87%
ROICexc(5y)52.56%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)47.22%
ROCE(5y)35.45%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y64.05%
ROICexc growth 5Y48.31%
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
F-Score8
Asset Turnover1.42
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 118.36% | ||
| Cap/Sales | 1.54% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 121.25% | ||
| Profit Quality | 138.61% | ||
| Current Ratio | 0.43 | ||
| Quick Ratio | 0.43 | ||
| Altman-Z | 7.68 |
F-Score8
WACC10.55%
ROIC/WACC10.9
Cap/Depr(3y)142.96%
Cap/Depr(5y)144.54%
Cap/Sales(3y)2.07%
Cap/Sales(5y)2.41%
Profit Quality(3y)141.71%
Profit Quality(5y)142.32%
High Growth Momentum
Growth
EPS 1Y (TTM)26.53%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%12.73%
EPS Next Y13.52%
EPS Next 2Y11.72%
EPS Next 3Y11.39%
EPS Next 5Y10.11%
Revenue 1Y (TTM)9.94%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%14.24%
Revenue Next Year16.85%
Revenue Next 2Y12.67%
Revenue Next 3Y11.46%
Revenue Next 5Y10.93%
EBIT growth 1Y25.19%
EBIT growth 3Y31.04%
EBIT growth 5Y28.55%
EBIT Next Year22.27%
EBIT Next 3Y13.24%
EBIT Next 5Y12.21%
FCF growth 1Y55.28%
FCF growth 3Y34.54%
FCF growth 5Y25.47%
OCF growth 1Y50.59%
OCF growth 3Y32.23%
OCF growth 5Y24.7%